I agree, though is usually through share issuance and dilution.
A Captial raise at these levels here would not be fun at all and cause mass undue dilution just to get through the smallest revenue therapy.
I would hope with the amount of medical conferences that MSB board have been to over the last two decades and have made many connections, then they can convince some company to partner or heart or back in US now to see them through.
Terms are the key to see how much MSB can grow from here.
Ann: Mesoblast Type A Meeting with FDA, page-150
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.46 |
Change
0.005(0.34%) |
Mkt cap ! $1.649B | |||
| Open | High | Low | Value | Volume |
| $1.46 | $1.49 | $1.44 | $1.552M | 1.066M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 29983 | $1.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.46 | 35244 | 10 |
View Market Depth
| Last trade - 11.31am 21/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |